var data={"title":"Caprylidene: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Caprylidene: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/482750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=caprylidene-patient-drug-information\" class=\"drug drug_patient\">see &quot;Caprylidene: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652170\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Axona</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24657374\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Medical Food</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652180\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Alzheimer disease (AD):</b> Oral: Initial: 10 g once daily for 2 days; increase dose in 10 g increments every 2 days until reaching 40 g once daily on day 7; titrate slower if the patient experiences adverse events;  Maintenance: 40 g once daily  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b>  If adverse events occur, discontinue caprylidene until symptoms resolve (generally within 2 to 3 days). Restart caprylidene with the initial dose.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652181\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652182\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652184\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">The contents of each packet of caprylidene should be added to 4 to 8 oz (118 to 236 mL) of water or other liquids, shaken or blended until fully mixed, and consumed 15-30 minutes after a full meal (preferably breakfast or lunch). Consumption following meals containing fats and proteins or adding ice to the drink may slow the digestion of MCTs and reduce the likelihood of developing GI symptoms; tolerability can also be improved if the drink is sipped over 30 minutes instead of consumed all at once.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034662\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Alzheimer disease:</b> For clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer disease (AD). Caprylidene is a medical food containing a proprietary formulation of MCTs, specifically caprylic triglyceride</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> A medical food is formulated to be administered enterally under the supervision of a physician and is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements are established by medical evaluation. Medical foods are not drugs and, therefore, are not subject to any FDA regulatory requirements that specifically apply to drugs (eg,  requirement for written/oral prescription prior to dispensing, premarket review or approval, proof of safety and efficacy).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24143202\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Diarrhea (10% to 24%), nausea (10% to 20%), abdominal distention (17%), flatulence (15% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7%), headache (6%), fatigue (4%), pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (10%), dyspepsia (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4%), rhinitis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distress, GI inflammation (exacerbation), increased blood urea nitrogen, increased serum creatinine, increased serum triglycerides, increased uric acid, syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652171\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Allergy to milk or soy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ketoacidosis: Use with caution in patients at risk for ketoacidosis such as patients with a history of alcohol abuse and poorly controlled diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of bradycardia, hypotension, or among patients taking medications that may induce these effects (eg, antihypertensives and cholinesterase inhibitors); fainting and dizziness has been infrequently reported among these groups. Use a gradual dose titration in patients at risk and emphasize administration after meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Gastrointestinal (GI) adverse effects (eg, abdominal cramping, diarrhea, dyspepsia) may result due to the rapid hydrolysis of medium-chain triglycerides in the gut and the resultant accumulation of high concentration of medium-chain fatty acids in the small intestine. Severe episodic diarrhea may occur with overusage.  Use with caution in patients with a history of GI inflammatory conditions such as irritable bowel syndrome, diverticular disease, chronic gastritis, and severe gastroesophageal reflux disease. OTC medications such as simethicone, antacids, and antidiarrheals may be useful for treating mild to moderate GI effects; advise patients to see healthcare provider if symptoms persist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metabolic syndrome: Elevated triglyceride values have been observed in patients with probable metabolic syndrome.  Periodically monitor triglyceride levels in patients who meet at least 3 of the following 5 criteria indicative of metabolic syndrome: Elevated waist circumference (&ge;40 inches in men, &ge;35 inches in women), blood pressure &ge;130/85 mm Hg, triglyceride &ge;150 mg/dL, reduced fasting HDL (&lt;40 mg/dL in men, &lt;50 mg/dL in women), and fasting glucose &ge;100 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with a history of renal dysfunction; mild increases in blood urea nitrogen (BUN), creatinine, or uric acid were reported in clinical trials.  Routine renal function monitoring is recommended in patients with a history of renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Component ingredients: Product contains caseinate (milk-derived protein), whey (milk), and lecithin (soy). Do not use in patients allergic to these component ingredients or milk or soy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24069987\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24069984\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=95044&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652186\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic triglyceride levels in patients who meet criteria indicative of metabolic syndrome; routine renal function tests in patients with a history of renal dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652175\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces hyperketonemia to provide an alternative energy substrate to glucose in the brain of patients with Alzheimer disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24652177\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Metabolism: Processed by lipases in the gut to medium-chain fatty acids (MCFAs); MCFAs under obligate oxidation in the liver and beta-oxidation in the liver mitochondria to form acetyl-CoA and acetoacetyl-CoA.  Acetyl-CoA and acetoacetyl-CoA when in excess are combined to form 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) which forms acetoacetate and beta-hydroxybutyrate (ie, ketone bodies) by HMG-CoA lyase.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Axona (caprylidene) [prescribing information]. Broomfield, CO: Accera; November 2012. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 95044 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24652170\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F24657374\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F24652180\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F24652181\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F24652182\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24652184\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24034662\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24143202\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F24652171\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24652172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F24069987\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F24069984\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24652186\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24652175\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F24652177\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/95044|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=caprylidene-patient-drug-information\" class=\"drug drug_patient\">Caprylidene: Patient drug information</a></li></ul></div></div>","javascript":null}